{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-006641","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.251248+00:00","generated_at":"2026-05-17T08:30:40.323342+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Phio advances Phase 1b skin cancer trial to 5th cohort; presents at conference","bullets":["Patients are now being treated in the 5th cohort of the ongoing Phase 1b clinical trial for skin cancer (PH-762).","Phio Pharmaceuticals will present at H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025.","CEO Robert Bitterman will deliver an update on the trial and discuss strategy and next steps for the PH-762 program."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-006641","json":"https://secwatch.observer/filing/0001683168-25-006641.json","markdown":"https://secwatch.observer/filing/0001683168-25-006641.md","text":"https://secwatch.observer/filing/0001683168-25-006641.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825006641/0001683168-25-006641-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316825006641/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:30:40.323342+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}